Meclofenamic Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium Channel Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant Properties

The voltage-dependent M-type potassium current (M-current) plays a major role in controlling brain excitability by stabilizing the membrane potential and acting as a brake for neuronal firing. The KCNQ2/Q3 heteromeric channel complex was identified as the molecular correlate of the M-current. Furthermore, the KCNQ2 and KCNQ3 channel α subunits are mutated in families with benign familial neonatal convulsions, a neonatal form of epilepsy. Enhancement of KCNQ2/Q3 potassium currents may provide an important target for antiepileptic drug development. Here, we show that meclofenamic acid (meclofenamate) and diclofenac, two related molecules previously used as anti-inflammatory drugs, act as novel KCNQ2/Q3 channel openers. Extracellular application of meclofenamate (EC50 = 25 μM) and diclofenac (EC50 = 2.6 μM) resulted in the activation of KCNQ2/Q3 K+ currents, heterologously expressed in Chinese hamster ovary cells. Both openers activated KCNQ2/Q3 channels by causing a hyperpolarizing shift of the voltage activation curve (-23 and -15 mV, respectively) and by markedly slowing the deactivation kinetics. The effects of the drugs were stronger on KCNQ2 than on KCNQ3 channel α subunits. In contrast, they did not enhance KCNQ1 K+ currents. Both openers increased KCNQ2/Q3 current amplitude at physiologically relevant potentials and led to hyperpolarization of the resting membrane potential. In cultured cortical neurons, meclofenamate and diclofenac enhanced the M-current and reduced evoked and spontaneous action potentials, whereas in vivo diclofenac exhibited an anticonvulsant activity (ED50 = 43 mg/kg). These compounds potentially constitute novel drug templates for the treatment of neuronal hyperexcitability including epilepsy, migraine, or neuropathic pain.

[1]  Keiichi Nagata,et al.  Kv3.4 subunits enhance the repolarizing efficiency of Kv3.1 channels in fast-spiking neurons , 2003, Nature Neuroscience.

[2]  K. Wilcox,et al.  Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. , 2002, Molecular pharmacology.

[3]  S. Burbidge,et al.  Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. , 2000, Molecular pharmacology.

[4]  D. A. Brown,et al.  Molecular correlates of the M‐current in cultured rat hippocampal neurons , 2002, The Journal of physiology.

[5]  B. Jensen,et al.  The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. , 2003, European journal of pharmacology.

[6]  D. A. Brown,et al.  Activation of Expressed KCNQ Potassium Currents and Native Neuronal M-Type Potassium Currents by the Anti-Convulsant Drug Retigabine , 2001, The Journal of Neuroscience.

[7]  B. Rudy,et al.  Developmental expression and functional characterization of the potassium-channel subunit Kv3.1b in parvalbumin-containing interneurons of the rat hippocampus , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  J. Lopez-Garcia,et al.  M-current modulators alter rat spinal nociceptive transmission: an electrophysiological study in vitro , 2004, Neuropharmacology.

[9]  S. Berkovic,et al.  A potassium channel mutation in neonatal human epilepsy. , 1998, Science.

[10]  B. Attali,et al.  Modulation of homomeric and heteromeric kcnq1 channels by external acidification , 2002, The Journal of physiology.

[11]  D. Strøbæk,et al.  KCNQ4 channel activation by BMS-204352 and retigabine , 2001, Neuropharmacology.

[12]  Thomas J. Jentsch,et al.  KCNQ5, a Novel Potassium Channel Broadly Expressed in Brain, Mediates M-type Currents* , 2000, The Journal of Biological Chemistry.

[13]  M. Lazdunski,et al.  Nonsteroid Anti-Inflammatory Drugs Inhibit Both the Activity and the Inflammation-Induced Expression of Acid-Sensing Ion Channels in Nociceptors , 2001, The Journal of Neuroscience.

[14]  D. A. Brown,et al.  Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone , 1980, Nature.

[15]  G. Yellen,et al.  Visual identification of individual transfected cells for electrophysiology using antibody-coated beads. , 1994, BioTechniques.

[16]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[17]  Alvaro Villarroel,et al.  The Identification and Characterization of a Noncontinuous Calmodulin-binding Site in Noninactivating Voltage-dependent KCNQ Potassium Channels* , 2002, The Journal of Biological Chemistry.

[18]  T. Jegla,et al.  Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells , 2001, British journal of pharmacology.

[19]  K. Kelly,et al.  Antiepileptic Drug Mechanisms of Action , 1993, Epilepsia.

[20]  Y. T. Lee,et al.  Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid. , 1999, European journal of pharmacology.

[21]  N. Marrion,et al.  Control of M-current. , 1997, Annual review of physiology.

[22]  V. Gribkoff,et al.  Synthesis and Structure−Activity Relationship of Acrylamides as KCNQ2 Potassium Channel Openers , 2004 .

[23]  I. Levitan,et al.  Calmodulin Is an Auxiliary Subunit of KCNQ2/3 Potassium Channels , 2002, The Journal of Neuroscience.

[24]  A. Dickenson,et al.  KCNQ/M Currents in Sensory Neurons: Significance for Pain Therapy , 2003, The Journal of Neuroscience.

[25]  L. Toro,et al.  Potentiation of large conductance KCa channels by niflumic, flufenamic, and mefenamic acids. , 1994, Biophysical journal.

[26]  Karin Dedek,et al.  Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Wei,et al.  Molecular Cloning and Functional Expression of KCNQ5, a Potassium Channel Subunit That May Contribute to Neuronal M-current Diversity* , 2000, The Journal of Biological Chemistry.

[28]  V. Gribkoff,et al.  (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. , 2003, Journal of medicinal chemistry.

[29]  D. A. Brown,et al.  Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells , 2003, The Journal of physiology.

[30]  I. Bjerre,et al.  BENIGN FAMILIAL NEONATAL CONVULSIONS , 1968, Acta paediatrica Scandinavica.

[31]  T. Jegla,et al.  Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. , 2000, Molecular pharmacology.

[32]  Michael A Rogawski,et al.  KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy , 2000, Trends in Neurosciences.

[33]  Mark Leppert,et al.  A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns , 1998, Nature Genetics.

[34]  T. Jentsch.  Neuronal KCNQ potassium channels:physislogy and role in disease , 2000, Nature Reviews Neuroscience.

[35]  B S Brown,et al.  KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. , 1998, Science.

[36]  C. Rundfeldt,et al.  The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[37]  L. Jan,et al.  M-channels: neurological diseases, neuromodulation, and drug development. , 2003, Archives of neurology.

[38]  Robin J. Leach,et al.  A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family , 1998, Nature Genetics.

[39]  B. Attali,et al.  Stilbenes and fenamates rescue the loss of IKS channel function induced by an LQT5 mutation and other IsK mutants , 1999, The EMBO journal.

[40]  R. Macdonald,et al.  Antiepileptic Drug Mechanisms of Action , 1993, Epilepsia.

[41]  G. Grover,et al.  The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism. , 1994, The Journal of pharmacology and experimental therapeutics.